Novo Nordisk CEO为美国药品价格辩护, Novo Nordisk CEO defends US drug prices, arguing they save taxpayers money on obesity costs.

Novo Nordisk CEO为美国高价封锁药Ozempic和Wegovy辩护, 指出他们最终将纳税人的钱节省在肥胖相关费用上。 Novo Nordisk CEO defends high US prices for blockbuster drugs Ozempic and Wegovy, stating that they ultimately save taxpayers money on obesity-related costs. Lars Fruergaard Jørgensen 首席执行官Lars Fruergaard Jørgensen驳回了关于该公司作为毒品卡特尔运作的指控,并将在下个月参议院委员会作证时讨论其糖尿病和减重药物的价格问题。 CEO Lars Fruergaard Jørgensen dismissed accusations that the company operates as a drug cartel and will address pricing of its diabetes and weight loss drugs in testimony before a Senate committee next month. 批评者认为,这些药品的高成本并不能抵消增加的药品开支。 Critics argue that the high cost of these drugs does not offset increased spending on them.